Engineered Protein ACT-101 Shows Potential in Mouse Model of Colitis, Study Shows

Engineered Protein ACT-101 Shows Potential in Mouse Model of Colitis, Study Shows
Researchers have found that Alpha Cancer Technologies' ACT-101, an engineered protein similar to the human alpha fetoprotein (hAFP), can protect mice from developing bowel inflammation. This finding resulted from a preclinical study that was the subject of a poster presentation titled, “Anti-inflammatory properties of recombinant human alpha-fetoprotein (rhAFP) in the model of TNBS-induced colitis,” presented at the World Congress of Gas
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *